Locally Advanced or Metastatic ER+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Locally Advanced or Metastatic ER+/HER2- Breast Cancer Market Outlook

Thelansis’s “Locally Advanced or Metastatic ER+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Locally Advanced or Metastatic ER+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Locally Advanced or Metastatic ER+/HER2- Breast Cancer Overview

Human epidermal growth factor receptor 2 (HER2)–positive breast cancer accounts for approximately 15% to 20% of all breast cancer cases. Around 60–70% of HER2-positive breast cancer cases exhibit co-expression of hormone receptors (HRs). This co-expression influences the response to both anti-HER2–directed and endocrine therapy, primarily due to the "crosstalk" between the estrogen receptor (ER) and HER2 pathways. Historically, the HER2-positive breast cancer subtype was linked to heightened risks of systemic and brain metastases and poor overall survival. However, introducing trastuzumab has significantly improved outcomes for HER2-positive patients, aligning them with those of patients with luminal tumors. Presently, the recommended initial treatment for HER2-positive metastatic breast cancer involves dual HER2 antibody therapy using pertuzumab/trastuzumab alongside a taxane. Following disease progression, trastuzumab emtansine (T-DM1) becomes the standard of care. Lapatinib, which inhibits HER2 and epidermal growth factor receptor type 1 (EGFR1), was the first FDA-approved tyrosine kinase inhibitor (TKI) for HER2-positive metastatic breast cancer treatment.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: